RecruitingPhase 3NCT06443502

A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

Studying Pouchitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Takeda
Principal Investigator: Study Director
Takeda
Intervention: Vedolizumab(drug)
Enrollment: 30 target
Eligibility: 2-17 years · All sexes
Timeline: 2024 – 2029

Study locations (14)

UZ Leuven, Leuven, Vlaams-Brabant, Belgium
Children's Hospital Zagreb, Zagreb, Croatia
Fakultni nemocnice v Motole, Pediatricka klinika 2, Prague, Czechia
Sotiria Thoracic Diseases Hospital, Dpt. of Gastroenterology, Building Z, Athens, Attica, Greece
Shaare Zedek Medical Center, Jerusalem, Israel
Schneider Children's Medical Center of Israel, Petah Tikva, Israel
Istituto G Gaslini Ospedale Pediatrico IRCCS, Genova, Italy
Azienda Ospedaliero Universitaria, Policlinico Gaetano Martino, Messina, Italy
AOU dell'Universita degli Studi della Campania Luigi Vanvitelli, Naples, Italy
Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy
IRCCS Materno Infantile Burlo Garofolo, Trieste, Italy
Instytut Pomnik-/Centrum Zdrowia dziecka, Warsaw, Poland
Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona, Spain
Hospital Universitari I Politecnic La Fe de Valencia, Valencia, Spain

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06443502 on ClinicalTrials.gov

Other trials for Pouchitis

Additional recruiting or active studies for the same condition.

See all trials for Pouchitis →

← Back to all trials